R.I. Senate introduces health care legislative package
Nine bills arriving soon on the Rhode Island Senate floor aim to make health care more affordable and accessible for Rhode Islanders.
The legislative package was announced Wednesday morning by Senate leadership and Sen. Melissa Murray, a Woonsocket Democrat who now chairs the Senate Committee on Health and Human Services. Murray was appointed last month to fill the vacancy left by Sen. Joshua Miller, who decided not to seek re-election last year.
'The bills we are highlighting with this announcement are key parts of the Senate's action on health care, but there is a great deal of other extremely important work being done by many of our colleagues,' Murray said in a statement. 'Solving this crisis cannot be done through a single piece of legislation, or by one collection of bills.'
Murray's contribution to the stack of bills would eliminate prior authorization for therapies and medical services ordered by primary care doctors. The bill does include some exceptions that the potential law 'shall not be construed to prohibit prior authorization requirements for brand-name prescription drugs and controlled substances,' according to its text. Services ordered by doctors with documented histories of fraud or abuse could also continue to be subject to prior authorization.
Murray said in a statement the bill is designed to expedite care for patients and prevent them from getting caught up in insurance obstacles. 'It is the doctors, not insurers, who know best what care is needed for their patients. And we need our primary care doctors focused on providing care, not haggling with insurance companies,' she stated.
Prospect asks federal bankruptcy judge to expedite sale of Roger Williams, Fatima hospitals
Senate President Dominick J. Ruggerio pointed to health care issues on his own turf as indicative of the bigger challenges facing Rhode Islanders. He cited the importance of Our Lady of Fatima Hospital in North Providence, which together with Roger Williams Medical Center in Providence, is being sold by cash-strapped Prospect Medical Holdings. The sale of both safety net hospitals to prospective buyer The Centurion Foundation must be approved by a federal bankruptcy judge.
'In my own community of North Providence, the situation surrounding Fatima Hospital's future has exemplified many of the challenges we are working to address, and driven home the very real, very serious consequences for Rhode Island families,' Senate President Dominick J. Ruggerio said in a statement. 'With the bills in this package, and many other pieces of legislation introduced by my colleagues, the Senate remains focused on making health care less costly, and easier to get, for every resident of our state.'
Sen. Majority Leader Valarie Lawson's bill would see people over age 65 enrolled in Medicare Parts A and B 'guaranteed' the right to enroll in supplemental coverage to cover services not in their standard plan. The enrollment period would be chosen by the state's Office of the Health Insurance Commissioner.
The health care system 'can be a time-consuming headache, for both providers and patients,' especially when it comes to finding care or getting prescriptions, Lawson said in a statement.
Also included in the package:
Medical debt relief. One bill by Sen. John Burke, a West Warwick Democrat, would cap the interest rate on new medical debt to be between 1.5% and 4% annually. Another led by Sen. Jake Bissaillon, a Providence Democrat, would stop liens being placed on homes because of medical debt.
Spread pricing limits. Two bills — one by freshman Sen. Lori Urso, a Pawtucket Democrat, and the other by Sen. Linda Ujifusa, a Portsmouth Democrat — would prohibit spread pricing by health insurers. The practice can be used by pharmacy benefit managers, which often handle prescription drug benefits for health insurance companies, and involves charging payers more for a drug than what it costs at the pharmacy. The benefit managers then keep the difference. Ujifusa's bill specifically targets Medicaid managed plans; Urso's bill focuses on commercial insurers.
Financial aid for doctor education. A bill by Sen. Brian Thompson, a newly elected Woosocket Democrat, would use Medicaid funding to support graduate medical education programs in areas such as trauma care, primary care and maternal and mental health.
Vaccine delivery. A bill by Sen. Robert Britto, a Rumford Democrat, would clarify state law regarding pharmacist administration of vaccines.
Cutting through licensing red tape. A bill by Sen. Peter A. Appollonio Jr., a freshman Warwick Democrat, wants to address medical license backlogs by permitting the Rhode Island Department of Health to evaluate medical licensing applications if the relevant public body which would normally approve it has not been able to meet quorum in the past 30 days. The Rhode Island Department of Health Could approve or deny the license.
The bills, once introduced, will go to the Senate Committee on Health and Human Services for initial hearings.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Legislature overrides governor's veto to enact controversial law: 'An awful turning point'
Legislature overrides governor's veto to enact controversial law: 'An awful turning point' The North Carolina legislature overrode the governor's veto in order to approve a bill that could slow future environmental regulations. What's happening? Having already passed through the State House and Senate this past spring, House Bill 402 was vetoed by Democratic Governor Josh Stein in June. Republican lawmakers found enough votes to override the veto in late July, making it law, along with another seven previously vetoed bills. Also known as the Regulations from the Executive in Need of Scrutiny — or REINS — Act, HB 402 aims to place additional restrictions on the passage of any new environmental regulation in the state. According to North Carolina Health News, the new law will require any environmental regulation "with a projected financial impact" of $1 million over five years to be approved by a two-thirds majority of the body making the rule. For anything over $10 million, it requires unanimous approval. And for any regulation projected to cost $20 million or more, it requires formal approval from the state's General Assembly. Why is this concerning? This law could make it virtually impossible for any kind of real, substantive regulation to be implemented, environmental advocates say. "Lawmakers who passed this bill did not have the best interests of North Carolinians at heart," said Mary Maclean Asbill, director of the state's Southern Environmental Law Center's office. "This new law marks an awful turning point for families and communities across North Carolina when elected officials in the state legislature ignore serious illnesses and deaths in favor of polluters' profits," she continued in a release, per NCHN. The outlet noted that House Speaker Destin Hall, a Republican, said, "What we had in the REINS Act was a situation where if you have a regulation that is extremely expensive, our position is that it's something that [the legislature] needs to take a look at." Meanwhile, environmental advocates say that viewing each new regulation through a strictly financial lens — rather than through a lens that weighs the cost against the potential benefits for public health and essential ecosystems — will make passage of new legislation practically unobtainable. What's being done in North Carolina? While this legislation's finalization is certainly a blow to many environmentalists and public health advocates, their hopes are not completely lost in North Carolina. A pair of bills, HB 569 and Senate Bill 666, could still have major impacts on the state's environmental regulations, according to NCHN. Do you worry about having toxic forever chemicals in your home? Majorly Sometimes Not really I don't know enough about them Click your choice to see results and speak your mind. HB 569 would require polluters to reimburse public water systems for clean-ups of per- and polyfluoroalkyl substances. SB 666 would charge the Environmental Management Commission with setting regulatory limits on PFAS. It's unclear how either bill could be impacted by HB 402 becoming law, though, and the status of both bills remains uncertain at this stage. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword


Axios
2 days ago
- Axios
Abortion pill fight reaches pharmacy board rooms
A year after the Supreme Court preserved abortion pill access, the fight over dispensing mifepristone is shifting from courtrooms to boardrooms as anti-abortion forces press pharmacy chains not to sell the drugs. The big picture: Costco last week said it won't stock mifepristone at its more than 500 pharmacies. Conservative groups are pushing other pharmacies — including Walgreens and CVS, which offer the pills in states where abortion is legal — to follow suit. "We can effectuate real change by talking to these companies and engaging with them," said Michael Ross, legal counsel for Alliance Defending Freedom's corporate engagement team. "Hopefully Costco will be a trendsetter." But those efforts are making retail pharmacies a new ground zero in the fight over abortion access. Costco got swift criticism from one of its home-state senators, Washington Democrat Patty Murray, for accommodating "far-right extremists" she said were whipsawing the availability of basic care. Between the lines: Pharmacy chains were destined to be involved after the Food and Drug Administration in 2023 allowed retailers to apply for certification to dispense mifepristone, which is part of a two-step protocol used to medically end a pregnancy through 10 weeks. The drug, which FDA first approved in 2000, has traditionally been dispensed at doctors' offices, hospitals or health clinics. But as states across the country restrict abortion, mifepristone prescribing via telehealth has significantly increased. State of play: Costco says it won't pursue approval to dispense mifepristone because demand for the drug is low. The company's understanding is that patients generally get the drug directly from their medical providers, it said in an email. But the decision, which reportedly came after more than a year of deliberations, is one anti-abortion groups have been pushing for. It extends beyond Costco's membership, since nonmembers can fill prescriptions at its drug counters. Last August, Alliance Defending Freedom led a coalition including thousands of Costco cardholders, financial advisers and consultants in urging the retailer not to offer mifepristone. "Costco ... needs to carefully consider the cost of alienating its diverse customers and potential customers just to boost one product in its pharmacy, which is one of its ancillary lines of business," their letter said. That pressure campaign followed New York City Comptroller Brad Lander (D) sending letters to Costco and other pharmacies, advocating that they get clearance to fill prescriptions where legal. "Making mifepristone available benefits customers and employees and increases sales, while also generating long-term shareholder value," Lander wrote to Costco last year. But abortion foes have allied with investor groups like Inspire Investing to warn Costco, Walmart, Albertsons, Kroger and other retail pharmacy operators as well as drug distributors to stay out of divisive political issues that could alienate customers and investors. "We say, OK, mifepristone may be a very small part of your sales, but look at all of the different backlash that you might be introducing, the different regulatory backlash from the Trump admin and the legal risk," Ross said. The Trump administration, Congress or the Supreme Court could still change requirements around the drug. The Supreme Court in 2024 preserved access to mifepristone, deciding that doctors who asked justices to stop the FDA's relaxation of restrictions around the drug didn't have standing, without ruling on the merits. In May, HHS Secretary Robert F. Kennedy Jr. said he'd directed the FDA to "to review the latest data on mifepristone" — a move that could restrict future availability. Other large pharmacy chains like Walmart, Kroger and Albertsons have not made public decisions on mifepristone dispensing. Kroger told Axios it's still reviewing the FDA's mifepristone drug safety program and will continue to align dispensing practices with federal and state law. Walmart declined to comment, and Albertsons did not respond. The other side: Curbing mifepristone access could make it even harder for women to access safe abortions, as well as miscarriage care, for which it has an off-label use. "By refusing to offer mifepristone, Costco has chosen politics over science, fear over facts, and ideology over the rights of its customers," Mini Timmaraju, CEO of advocacy group Reproductive Freedom for All, said in a statement last Friday. What we're watching: How Walgreens and CVS respond to pressure to stop filling mifepristone prescriptions.


Newsweek
2 days ago
- Newsweek
Iowa Democrat Drops Out of Senate Race, Endorses Rival
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Iowa Democratic Representative J.D. Scholten announced Monday that he is suspending his 2026 U.S. Senate campaign and endorsing fellow Democratic legislator Josh Turek in the primary race to potentially challenge Republican Senator Joni Ernst. Newsweek reached out to Scholten via email on Monday for comment. Why It Matters Scholten's endorsement consolidates Democratic support around healthcare advocacy, with Turek bringing a personal perspective to the issue. The two-time Paralympic gold medalist said his family relied on public assistance programs like Medicaid, as well as Iowa's Area Education Agencies and free summer lunch program as he was growing up, having gone through 21 surgeries by the age of 12 for spina bifida, according to his official campaign biography. The 2026 Iowa Senate race represents a critical opportunity for Democrats in a state that has shifted increasingly Republican in recent cycles. Senator Ernst's response to healthcare concerns has become a focal point for Democratic challengers seeking to make the race competitive. An important update 👉 Today I'm suspending my campaign and endorsing Josh Turek. We can't sit by while healthcare is ripped from millions of Americans and there's no better Democrat in Iowa to hold Joni to account for her cruelty than my friend fighter State Rep. Josh Turek. — J.D. Scholten (@JDScholten) August 18, 2025 What To Know Scholten, a Sioux City Democrat, entered the race in June after Ernst sparked controversy for responding to comments at a town hall about Medicaid cuts. "People are not ... well, we all are going to die," the senator said in part. Ernst's office later clarified to news outlets that she was attempting to make a broader philosophical point about mortality, not specifically about Medicaid policy. Turek, a Democrat from Council Bluffs, launched his campaign on Tuesday. The endorsement comes as both lawmakers represent western Iowa districts and share backgrounds as athletes serving in the state legislature. Scholten, a professional baseball pitcher for the minor league Sioux City Explorers, said he and Turek share many similarities as athletes representing western Iowa at the Statehouse. The Democratic primary field remains crowded despite Scholten's exit. Iowa Senator Zach Wahls, D-Coralville, Des Moines School Board Chair Jackie Norris and Nathan Sage, former Knoxville Chamber of Commerce director, are running for the seat, alongside Turek. On the Republican side, Jim Carlin, a former state lawmaker and Joshua Smith, who has run as a Libertarian candidate in previous elections, are also campaigning for the GOP nomination. Ernst has not officially said if she plans to run for reelection in 2026, though she has told reporters an announcement would be "coming soon." She also told a GOP audience last week that Democrats can "bring it on" in the 2026 election. The lawmaker has raised nearly $1.8 million in the first half of 2025 and scheduled an October fundraiser, possibly signaling preparations for a reelection campaign, the AP reports. Early polling of the race shows the senator with a slight advantage in Iowa. A June Public Policy Polling survey found that Ernst would lead a generic Democrat by about two percentage points—45 percent to 43 percent, with 12 percent still unsure. The poll did not ask voters about specific Democratic candidates. The poll surveyed 568 Iowa voters. What People Are Saying Scholten in a statement on Monday in part: "There are still so many issues facing Iowans today, but we can't sit by while healthcare is ripped from millions of Americans. And there is no better Democrat in Iowa to talk about healthcare issues than my friend: State Rep. Josh Turek." Scholten on his endorsement decision in part: "From the very beginning, I thought a prairie populist athlete from Western Iowa would be the best candidate to win in the General election. I still do, but instead of me, I have complete confidence that Josh Turek can take this on." Turek responding to Scholten's message on X: "I am honored to have the support of J.D. Over the last several years, J.D. and I have fought alongside one another in the state legislature to lower costs for Iowa's families, to make health care more affordable and accessible, to make housing more affordable, and to make life a little bit easier and a little bit better for Iowa's families." He concluded: "We have an incredible opportunity to beat Joni Ernst in 2026, and I'm proud to join forces with J.D." JD Scholten, running for congress in Iowa's 4th Congressional District against Steve King, waves to supporters outside the Wing Ding Dinner on August 9, 2019 in Clear Lake, Iowa. JD Scholten, running for congress in Iowa's 4th Congressional District against Steve King, waves to supporters outside the Wing Ding Dinner on August 9, 2019 in Clear Lake, Iowa. ALEX EDELMAN/AFP via Getty Images What Happens Next? Turek and Scholten will hold an event in Council Bluffs Monday evening. Ernst is expected to formally announce her potential reelection campaign within the coming weeks. Reporting from the Associated Press contributed to this article.